Skip to main
GERN
GERN

Geron (GERN) Stock Forecast & Price Target

Geron (GERN) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 6%

Bulls say

Geron Corp's positive outlook is primarily supported by the anticipated revenue growth from the recently approved Rytelo in the European Union, which is expected to begin generating income in 2026, with further potential expansion from an additional approval anticipated in the first half of 2025. The company’s strategic focus on educating healthcare providers and increasing awareness of Rytelo is likely to enhance its market penetration, especially in the treatment of low-risk myelodysplastic syndromes and relapsed/refractory myelofibrosis, potentially doubling the commercial opportunity. Moreover, the experience of key board members and the proactive management strategies reinforce confidence in Geron's ability to navigate the complexities of the oncology market and capitalize on the therapeutic benefits offered by Rytelo.

Bears say

Geron Corp's stock outlook is negatively impacted by a slowdown in the momentum of the Rytelo launch in lower-risk myelodysplastic syndromes, with management reporting flat revenue trends over recent months. The reliance on third-line patients for the majority of Rytelo prescriptions has resulted in disappointing uptake among second-line patients, which may delay revenue growth for several quarters. Furthermore, lowered peak sales projections for Rytelo from $1.2 billion to $1.0 billion reflect ongoing concerns about commercial competition and potential regulatory or clinical risks that could hinder the company's prospects.

Geron (GERN) has been analyzed by 18 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Geron and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Geron (GERN) Forecast

Analysts have given Geron (GERN) a Buy based on their latest research and market trends.

According to 18 analysts, Geron (GERN) has a Buy consensus rating as of Jul 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.01, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.01, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Geron (GERN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.